The legislation, advocated by both retail pharmacy and the pharma industry, would advance collaboration among health and enforcement authorities to achieve drug abuse solutions that maintain patients’ legitimate access to medications.
The letter points out that copay increases place financial burdens on TRICARE beneficiaries and restrict patient access. In addition, restricting patient access could adversely impact medication compliance and actually increase health costs.
So far in 2016, there have been multiple Part D plans and PBMs that have been utilizing MAC drug pricing values that are "far below what would be considered to be reasonably approaching market prices for drugs," the letter noted.
Global Citizen is reporting that GlaxoSmithKline will be granting licenses to generics manufacturers in lower middle-income countries in a move aimed at increasing access to medicine in low-income countries. The company announced the changes at the end of March, noting that rather than attempting to enforce its patents, it would move to a licensing model, charging a small fee to generics manufacturers. (Global Citizen)
The study found that Walgreens pharmacy patients who used a multi-faceted medication adherence program had a 3% higher medication adherence rate and lower healthcare costs than those who use other pharmacies.
The report attributes the growth to a concurrent increase in chronic pain in the United States, stemming from an aging population and more incidences of such chronic diseases as diabetes, obesity, cancer, arthritis and cardiovascular disease.
Deloitte’s new whitepaper, “Retail health & wellness: Innovation, convergence and healthier consumers” offers background and insights into how and why retailers are making the large shift toward more robust health and wellness offerings.
The complaint alleges that Endo paid Impax Laboratories and Watson Laboratories, which were the first companies to file for FDA approval for generics of Endo’s Opana ER and Lidoderm, to delay their generic product launches.